Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Roche says biotech bubble pushes midsize buys out of reach

The biotechnology sector is in a “bubble”, pushing prices for medium-sized companies with experimental drugs in late-stage development out of reach, the chief executive of drugmaker Roche said on Tuesday.   “I think this bubble will burst at some point,” Severin Schwan told Reuters in an interview during a visit to London. The Swiss company […]

Read More »

FORUM Pharma Halts Clinical Trials for Alzheimer’s and Schizophrenia Drug

The U.S. Food and Drug Administration (FDA) advised Waltham, Mass.-based FORUM Pharmaceuticals to halt its clinical trials of encenicline for Alzheimer’s disease yesterday. The FDA cited a small number of serious gastrointestinal (GI) side effects in the studies. As a result, FORUM halted the trial, discontinuing the medication and no new patients will be recruited […]

Read More »

Anthera Shares Slump as Zenyaku Kogyo Backs Out of Blisibimod Deal

Hayward, Calif.-based Anthera Pharmaceuticals, Inc. (ANTH) announced today that its Japanese development partner, Zenyaku, had ended a December 2014 Collaboration and License Agreement. The deal will terminate Jan. 7, 2016. The original deal was for the development of blisibimod in Japan. Blisibimod is a selective peptibody antagonist of the B-cell activating factor (BAFF) cytokine. It […]

Read More »

Mylan Begins Hostile Bid for Perrigo

Mylan NV on Monday officially took its takeover bid directly to shareholders of Perrigo Co. (PRGO 0.88 %) after the company’s board and management publicly rebuffed previous advances.   Mylan is offering $75 in cash and 2.3 shares of Mylan for each Perrigo share held, valued at about $187 based on Friday’s closing price. Perrigo’s shares […]

Read More »

Dr. Reddy’s Laboratories Signs Commercialization Deal with Hatchtech

HYDERABAD, India–(BUSINESS WIRE)–Dr. Reddy’s Laboratories (NYSE: RDY) today announced the signing of a commercialization deal with Hatchtech, an Australian pharmaceutical company developing an innovative prescription head lice product, Xeglyze™ Lotion. The exclusive rights for this product are applicable for the territories of the United States, Canada, India, Russia and the CIS, Australia, New Zealand and […]

Read More »

Actelion in talks with ZS Pharma amid surge in biotech deal-making

Swiss drugmaker Actelion Ltd has initiated preliminary discussions with U.S. biotech company ZS Pharma Inc, marking the latest bout of deal-making in a healthcare sector that has seen a wave of recent takeovers. Actelion, Europe’s biggest biotech company, and ZS Pharma both issued statements late on Thursday stating that they had held preliminary discussions, but […]

Read More »

Nine-Person Gencia Inks $500 Million Collaboration Deal with Takeda

Takeda Pharmaceutical Company, headquartered in Osaka, Japan, and Charlottesville, Va.-based Gencia LLC announced today a $500 million partnership deal. The two companies plan to work on a new class of small molecules as possible drugs for hematological and inflammatory diseases. The focus of the collaboration will be on Mitochondrial Agonists of the Glucocorticoid Receptor (MAGR), […]

Read More »

AstraZeneca PLC And Starpharma Ink Drug Delivery Deal Worth up to $450 Million

MELBOURNE, Australia— AstraZeneca PLC[2] (AZN[3]) struck a deal worth up to $450 million with Australia-based Starpharma[4] to license that company’s DEP drug delivery platform for use with its oncology medications. Starpharma’s licensing agreement with AstraZeneca focuses on novel compounds, and not on unmodified drugs in currently marketed formulations. AstraZeneca did not disclose which oncology drug […]

Read More »

Lannett to Acquire UCB’s Kremers Urban Unit

Lannett Company Inc. has agreed to buy UCB SA’s Kremers Urban Pharmaceuticals Inc. for $1.23 billion. The deal, with tax benefits expected to top $100 million, also calls for potential contingency payments under sales and timing thresholds. Lannett said it expects the deal to close in the fourth quarter. Lannett’s shares, up 15% this year, […]

Read More »

Sanofi Terminates a $200 Million NaP2b Development Deal With Ardelyx

Paris-based Sanofi (SNY) announced yesterday that it was terminating its option and license agreement with Fremont, Calif.-based Ardelyx (ARDX) for its NaP2b inhibitors. The termination will go into effect Sept. 30, 2015.   On Feb. 24, 2014, Ardelyx inked a licensing deal with Sanofi for its NaP2b inhibitor program, also known as NaPi2b, Npt2b and […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!


Ad Right Bottom